Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The New NCI Precision Medicine Trials.
Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. Harris LN, et al. Among authors: doroshow jh. Clin Cancer Res. 2023 Dec 1;29(23):4728-4732. doi: 10.1158/1078-0432.CCR-23-0917. Clin Cancer Res. 2023. PMID: 37531248 Free PMC article.
Designing phase 0 cancer clinical trials.
Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Murgo AJ, et al. Among authors: doroshow jh. Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560. Clin Cancer Res. 2008. PMID: 18559582 Free PMC article.
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G; Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Kummar S, et al. Among authors: doroshow jh. Eur J Cancer. 2009 Mar;45(5):741-6. doi: 10.1016/j.ejca.2008.10.024. Epub 2008 Dec 16. Eur J Cancer. 2009. PMID: 19091546 Free PMC article. Review.
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. Kummar S, et al. Among authors: doroshow jh. Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3. Clin Cancer Res. 2012. PMID: 22307137 Free PMC article. Clinical Trial.
Development and use of integral assays in clinical trials.
Schilsky RL, Doroshow JH, Leblanc M, Conley BA. Schilsky RL, et al. Among authors: doroshow jh. Clin Cancer Res. 2012 Mar 15;18(6):1540-6. doi: 10.1158/1078-0432.CCR-11-2202. Clin Cancer Res. 2012. PMID: 22422406 Free PMC article.
Cediranib for metastatic alveolar soft part sarcoma.
Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L. Kummar S, et al. Among authors: doroshow jh. J Clin Oncol. 2013 Jun 20;31(18):2296-302. doi: 10.1200/JCO.2012.47.4288. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630200 Free PMC article. Clinical Trial.
Criteria for the use of omics-based predictors in clinical trials.
McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA. McShane LM, et al. Among authors: doroshow jh. Nature. 2013 Oct 17;502(7471):317-20. doi: 10.1038/nature12564. Nature. 2013. PMID: 24132288 Free PMC article.
448 results